Studies

Grayline Research Center is currently conducting the following studies. If you would like to learn more about them and to see if you are eligible to participate in one of them please call 940-322-1131.

FACTS

Click here to let us know you’re interested in participating in a study.


PTSD Study

If you’re struggling with PTSD, with or without medication, you could participate in this research study of an investigational PTSD drug.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole as Monotherapy or as combination therapy in the treatment of adults with Post-traumatic Stress Disorder

Age 18-65

Onset of PTSD symptoms for a minimum of 6 months and no longer than 15 years

Initial onset after the age of 16

Not currently receiving Zoloft


Sleep-Promoting Alzheimer’s Study

Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging study of Piromelatine in patients with mild dementia due to Alzheimer’s Disease.  (This study is promoted as helping AD with sleep. )

Has a reliable caregiver

Age 60-85

Currently on a stable dose of Alzheimer’s Disease medication

Has the ability to spend at least 2 hours per day exposed to daylight


Alzheimer’s Disease

To evaluate efficacy and safety in patients with mild to moderate Alzheimer’s Disease.

  • male or female 50 years or older
  • currently having memory problems
  • currently taking a stable dose of a cholinesterase inhibitor and/or memantine for at least 3 months
  • have a reliable caregiver

Alzheimer’s Disease

To evaluate efficacy and safety in patients with mild to moderate Alzheimer’s Disease.

  • male or female 50-85 years or older
  • currently having memory problems.
  • currently taking a stable dose of    Donepezil & Memantine for 3 months
  • have a reliable caregiver

Depression – Geriatric

To evaluate the efficacy and safety in patients with Geriatric Depression.

  • male or female 65 years of age or older
  • experiencing a major depression episode
  • failure to respond to an adequate trial of anti-depressant in the current episode.
  • Must currently be on an anti-depressant treatment and having an inadequate response

Depression – Mild to Moderate

To evaluate the efficacy, safety, and tolerability for adjunctive treatment of MDD.

  • male or female 18-65 years of age
  • current major depression episode of 8 weeks to 24 months in duration
  • failure to respond less than 50% improvement to an adequate trial of anti-depressant in the current episode.

Depression – Bipolar 1

To evaluate the efficacy and safety in patients with Bipolar 1 Depression.

  • male or female 18-65 years of age
  • current episode of depression of at least 4 weeks and exceeding 12 months
  • currently treated as an outpatient.
  • previous mixed or manic episode

Osteoarthritis of the Hip or Knee

To evaluate the efficacy and safety in patients with Osteoarthritis of the  hip or knee.

  • male or female 18 years of age or older
  • must have a pain level of 4 or greater in hip or knee
  • currently receiving oral NSAID therapy
  • documented history of opioid treatment with inadequate pain relief.

Osteoarthritis of the Knee

To evaluate the efficacy and safety in patients with Osteoarthritis of the knee.

  • male or female at least 50 years of age.
  • must have a pain level of 4 or greater in knee
  • able to undergo MRI
  • willing and able to take supplemental calcium and vitamin D